Michael Gelband’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Michael Gelband’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-394,211	Closed	-$1.03M	–	2834
2021 Q4	$1.03M	Buy	+394,211	New	+$1.19M	0.01%	1055
2020 Q1	–	Sell	-18,160	Closed	-$111K	–	1804
2019 Q4	$111K	Buy	+18,160	New	+$74.8K	﹤0.01%	1419

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

TCM

Towercrest Capital Management Newtown, Pennsylvania $717M AUM 15.39% 1-Year Est. Return

VPW

Vericrest Private Wealth Newtown, Pennsylvania $112M AUM

Michael Gelband's PHAS Position: Q1 2022 in Review

Michael Gelband sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 394,211 shares — an estimated $1.03M sold.

Michael Gelband first reported a position in PHAS in Q4 2019 and held it in 2 quarters. The position peaked at $1.03M in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

Michael Gelband reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Michael Gelband sold 394,211 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $1.03M.
Michael Gelband first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Michael Gelband's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.03M in Q4 2021.
56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.